Literature DB >> 11448931

The impact of p53 status on cellular sensitivity to antifolate drugs.

X Lu1, J Errington, N J Curtin, J Lunec, D R Newell.   

Abstract

The impact of p53 status on cellular sensitivity to antifolate drugs has been examined in seven human cell lines (A549, MCF7, T-47D, CCRF-CEM, COR-L23, A2780, and HCT-116) and p53 nonfunctional counterparts of two of the cell lines (HCT-116/N7 and A2780/CP70). p53 status was determined by sequencing and functional assays. The sensitivities of the cell lines to growth inhibition (sulphorhodamine B assay) produced by four antifolate drugs (Alimta, methotrexate, raltitrexed, and lometrexol) were studied. There was no clear relationship between functional p53 status and sensitivity to methotrexate or lometrexol, whereas a functional p53 status was possibly associated with resistance to Alimta- and raltitrexed-induced growth inhibition. In contrast, in the two pairs of related human tumor cell lines (HCT-116 and HCT-116/N7 and A2780 and A2780/CP70) cells with functional p53 were more sensitive to Alimta- and raltitrexed-induced growth inhibition (P = 0.002). Detailed studies were performed with the A2780 cell lines, and in the parental cells sensitivity to Alimta- and raltitrexed-induced cytotoxicity (clonogenic assay) was similar to the sensitivity determined in the sulphorhodamine B assay. However, in A2780/CP70 cells, 1 microM of drug resulted in only 40-60% growth inhibition yet > or = 85% cytotoxicity. After Alimta and raltitrexed exposure for < or = 72 h, there were no differences between the A2780 and A278/CP70 cell lines in cell cycle phase distribution, absolute cell number, or the induction of apoptosis. However, the cellular protein content of the A2780/CP70 cells was 3-6-fold higher than in A2780 cells after Alimta and raltitrexed treatment, suggesting that cells without functional p53 can maintain protein synthesis in the absence of cell division (unbalanced cell growth). In conclusion, the apparent impact of functional p53 status on sensitivity to antifolate drugs may depend upon the phenotypic/genotypic background as well as the assay used to measure cellular sensitivity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448931

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.

Authors:  Takahito Miyake; Sunila Pradeep; Sherry Y Wu; Rajesha Rupaimoole; Behrouz Zand; Yunfei Wen; Kshipra M Gharpure; Archana S Nagaraja; Wei Hu; Min Soon Cho; Heather J Dalton; Rebecca A Previs; Morgan L Taylor; Takeshi Hisamatsu; Yu Kang; Tao Liu; Sharon Shacham; Dilara McCauley; David H Hawke; John E Wiktorowicz; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

2.  UCH-L1 promotes invasion of breast cancer cells through activating Akt signaling pathway.

Authors:  Yanhong Luo; Jianfeng He; Chunlin Yang; Matthew Orange; Xingcong Ren; Nick Blair; Tao Tan; Jin-Ming Yang; Hua Zhu
Journal:  J Cell Biochem       Date:  2017-07-31       Impact factor: 4.429

Review 3.  RNAi technology: a revolutionary tool for the colorectal cancer therapeutics.

Authors:  Wei Lv; Chao Zhang; Jia Hao
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

4.  Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression.

Authors:  Natalia V Oleinik; Natalia I Krupenko; David G Priest; Sergey A Krupenko
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

5.  Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.

Authors:  Stefanie M Ueda; Kai Lee Yap; Ben Davidson; Yuan Tian; Vivek Murthy; Tian-Li Wang; Kala Visvanathan; Francis P Kuhajda; Robert E Bristow; Hui Zhang; Ie-Ming Shih
Journal:  J Oncol       Date:  2010-05-19       Impact factor: 4.375

6.  In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.

Authors:  An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

7.  Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed.

Authors:  Sang Hee Min; I David Goldman; Rongbao Zhao
Journal:  Cancer Chemother Pharmacol       Date:  2007-06-27       Impact factor: 3.333

8.  Selective tumor cell killing by triptolide in p53 wild-type and p53 mutant ovarian carcinomas.

Authors:  Jianyuan Wu; Qingdi Quentin Li; Huiping Zhou; Yinying Lu; Jueli M Li; Yao Ma; Li Wang; Tingting Fu; Xingjiang Gong; Michael Weintraub; Shuangchan Wu; Hong Ding
Journal:  Med Oncol       Date:  2014-06-01       Impact factor: 3.064

9.  Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Authors:  Victoria J Spanswick; Helen L Lowe; Claire Newton; John P Bingham; Alessia Bagnobianchi; Konstantinos Kiakos; Charles Craddock; Jonathan A Ledermann; Daniel Hochhauser; John A Hartley
Journal:  BMC Cancer       Date:  2012-09-28       Impact factor: 4.430

10.  Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Authors:  Jing-Yue Yao; Shu Xu; Yue-Ning Sun; Ye Xu; Qing-Long Guo; Li-Bin Wei
Journal:  Acta Pharmacol Sin       Date:  2021-06-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.